Limits...
Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay.

Takahashi R, Yokobori T, Osone K, Tatsuki H, Takada T, Suto T, Yajima R, Kato T, Fujii T, Tsutsumi S, Kuwano H, Asao T - Cancer Sci. (2016)

Bottom Line: Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients.However, previous studies using mouse models of peritoneal dissemination have not detected any drug effect against peritoneal micrometastasis.Therefore, it is a useful model to validate peritoneal micrometastasis formation and to evaluate drug efficacy without killing mice.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan.

Show MeSH

Related in: MedlinePlus

In vivo luciferase assay to evaluate drug efficacy on day 10. (a) Intense luminescence was observed in the no treatment (no treat) group. Mouse no. 10 in this group died on day 9. White arrows show areas of luminescence. In the cisplatin (CDDP) group, luminescence was observed in mouse no. 6, 16, and 18 but not in mouse no. 4. In the gemcitabine group, luminescence was observed in mouse no. 3, 8, and 14. (b) Luminescence intensity was calculated by Image J software. Luminescence intensity was significantly stronger in the no treatment group than that in the CDDP and gemcitabine groups.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814254&req=5

cas12872-fig-0003: In vivo luciferase assay to evaluate drug efficacy on day 10. (a) Intense luminescence was observed in the no treatment (no treat) group. Mouse no. 10 in this group died on day 9. White arrows show areas of luminescence. In the cisplatin (CDDP) group, luminescence was observed in mouse no. 6, 16, and 18 but not in mouse no. 4. In the gemcitabine group, luminescence was observed in mouse no. 3, 8, and 14. (b) Luminescence intensity was calculated by Image J software. Luminescence intensity was significantly stronger in the no treatment group than that in the CDDP and gemcitabine groups.

Mentions: In in vivo luciferase assay, on day 10, luminescence was observed in all three of the surviving mice in the no treatment group, in three of the four mice in the CDDP group (Fig. 3a), and in three of the five mice in the gemcitabine group. Luminescence intensity in the no treatment group was significantly stronger than that in the CDDP and gemcitabine groups (Fig. 3b).


Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay.

Takahashi R, Yokobori T, Osone K, Tatsuki H, Takada T, Suto T, Yajima R, Kato T, Fujii T, Tsutsumi S, Kuwano H, Asao T - Cancer Sci. (2016)

In vivo luciferase assay to evaluate drug efficacy on day 10. (a) Intense luminescence was observed in the no treatment (no treat) group. Mouse no. 10 in this group died on day 9. White arrows show areas of luminescence. In the cisplatin (CDDP) group, luminescence was observed in mouse no. 6, 16, and 18 but not in mouse no. 4. In the gemcitabine group, luminescence was observed in mouse no. 3, 8, and 14. (b) Luminescence intensity was calculated by Image J software. Luminescence intensity was significantly stronger in the no treatment group than that in the CDDP and gemcitabine groups.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814254&req=5

cas12872-fig-0003: In vivo luciferase assay to evaluate drug efficacy on day 10. (a) Intense luminescence was observed in the no treatment (no treat) group. Mouse no. 10 in this group died on day 9. White arrows show areas of luminescence. In the cisplatin (CDDP) group, luminescence was observed in mouse no. 6, 16, and 18 but not in mouse no. 4. In the gemcitabine group, luminescence was observed in mouse no. 3, 8, and 14. (b) Luminescence intensity was calculated by Image J software. Luminescence intensity was significantly stronger in the no treatment group than that in the CDDP and gemcitabine groups.
Mentions: In in vivo luciferase assay, on day 10, luminescence was observed in all three of the surviving mice in the no treatment group, in three of the four mice in the CDDP group (Fig. 3a), and in three of the five mice in the gemcitabine group. Luminescence intensity in the no treatment group was significantly stronger than that in the CDDP and gemcitabine groups (Fig. 3b).

Bottom Line: Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients.However, previous studies using mouse models of peritoneal dissemination have not detected any drug effect against peritoneal micrometastasis.Therefore, it is a useful model to validate peritoneal micrometastasis formation and to evaluate drug efficacy without killing mice.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan.

Show MeSH
Related in: MedlinePlus